用户名： 密   码：
注册 | 忘记密码？
药品详细

Vecuronium(维库溴铵)

化学结构式图
中文名
维库溴铵
英文名
Vecuronium
分子式
C34H57N2O4
化学名
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium
分子量
Average: 557.8274
Monoisotopic: 557.431833322
CAS号
50700-72-6
ATC分类
M03A 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍

Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem]

生产厂家
    封装厂家
    参考
    Synthesis Reference Not Available
    General Reference Not Available
    剂型
    规格
    化合物类型
    Type small molecule
    Classes
    • Steroids and Steroid Derivatives
    Substructures
    • Steroids and Steroid Derivatives
    • Carboxylic Acids and Derivatives
    • Anions
    • Acetates
    • Sterols
    • Ethers
    • Quaternary Ammonium Salts
    • Bicyclohexanes
    • Aliphatic and Aryl Amines
    • Heterocyclic compounds
    • Piperidines
    • Cations
    适应症
    药理
    Indication Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
    Pharmacodynamics Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.
    Mechanism of action Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.
    Absorption Not Available
    Volume of distribution Not Available
    Protein binding Not Available
    Metabolism
    100%
    Route of elimination Fecal (40-75%) and renal (30% as unchanged drug and metabolites)
    Half life 51–80 minutes
    Clearance Not Available
    Toxicity Not Available
    Affected organisms Not Available
    Pathways Not Available
    理化性质
    Properties
    State solid
    Experimental Properties
    Property Value Source
    melting point 228 °C PhysProp
    Predicted Properties
    Property Value Source
    water solubility 1.86e-05 g/l ALOGPS
    logP 2.07 ALOGPS
    logP 0.89 ChemAxon
    logS -7.5 ALOGPS
    pKa (strongest basic) 9.65 ChemAxon
    physiological charge 2 ChemAxon
    hydrogen acceptor count 3 ChemAxon
    hydrogen donor count 0 ChemAxon
    polar surface area 55.84 ChemAxon
    rotatable bond count 6 ChemAxon
    refractivity 169.31 ChemAxon
    polarizability 66.85 ChemAxon
    药物相互作用
    Drug Interaction
    Amikacin The agent increases the effect of muscle relaxant
    Aminophylline Theophylline decreases the effect of muscle relaxant
    Azathioprine The agent decreases the effect of the muscle relaxant
    Betamethasone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Carbamazepine Decreases the effect of muscle relaxant
    Clindamycin The agent increases the effect of muscle relaxant
    Colistimethate Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
    Corticotropin Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Cortisone acetate Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Dexamethasone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Fludrocortisone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Fosphenytoin Phenytoin decreases the effect of muscle relaxant
    Gentamicin The agent increases the effect of muscle relaxant
    Hydrocortisone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Lincomycin The agent increases the effect of muscle relaxant
    Mercaptopurine The agent dereases the effect of the muscle relaxant
    Methylprednisolone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Netilmicin The agent increases the effect of muscle relaxant
    Oxtriphylline Theophylline decreases the effect of muscle relaxant
    Phenytoin Phenytoin decreases the effect of the muscle relaxant
    Piperacillin The agent increases the effect of the muscle relaxant
    Polymyxin B Sulfate Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
    Prednisolone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Prednisone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    Quinidine The quinine derivative increases the effect of the muscle relaxant
    Quinine Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided.
    Theophylline Theophylline decreases the effect of the muscle relaxant
    Tobramycin The agent increases the effect of the muscle relaxant
    Triamcinolone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
    食物相互作用
    Not Available

    返回 | 收藏